ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0277

Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria

Ali Duarte-Garcia1, Mehmet Hocaoglu2, Shirley-Ann Osei-Onomah3, Jesse Dabit1, Rachel Giblon1 and Cynthia Crowson4, 1Mayo Clinic, Rochester, MN, 2University of Maryland Medical Center Midtown Campus, Baltimore, MD, 3Mayo Clinic, Rochester, 4Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN

Meeting: ACR Convergence 2020

Keywords: classification criteria, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Classification criteria are standardized definitions required to identify well defined cohorts of patients for research. In practice they are also used as a framework for the diagnosis of diseases with heterogeneous manifestations such as Systemic Lupus Erythematosus (SLE). Recently the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE was published. The sensitivity and specificity of the 2019 EULAR/ACR criteria are different from the 1997 ACR criteria and the 2012 Systemic Lupus International Collaborating Clinics (SLICC) criteria. The effect on the incidence estimations of the disease using different criteria has not been studied. A reason to develop the new EULAR/ ACR criteria was to classify patients earlier in their disease process; however it has not been proven if this was indeed accomplished. We aimed to 1) estimate the incidence and time-to-classification of SLE using the 1997 ACR, 2012 SLICC and 2019 EULAR/ACR criteria.

Methods: We identified potential incident SLE cases from 2000-2018 in a geographically well-defined population using diagnostic codes for cutaneous and systemic lupus and the following laboratory measures: anti-nuclear antibodies, anti-double stranded DNA, anti-Sm, anticardiolipin, anti-beta 2 glycoprotein 1 antibodies, complement, coombs and lupus anticoagulant. Clinical data included in the 1997 ACR, 2012 SLICC and 2019 EULAR/ACR criteria were abstracted through chart reviews. If a disease manifestation could be better explained by another condition rather than SLE, it was not counted towards the criteria. We defined the time-to-classification based on the first lupus-attributable disease manifestation ever documented in the record to the time meeting criteria by each of the three definitions. Incidence rates were age and/or sex adjusted to the estimated 2010 white population of the US. To compute 95% confidence intervals for incidence rates, it was assumed that the number of incident cases followed a Poisson distribution. Time-to-classification among different criteria was compared using signed rank test.

Results: There were 127 incident cases that met the EULAR/ACR 2019 criteria, corresponding to an adjusted incidence of 4.7 per 100,000 (95% CI, 3.9-5.5). The incidence was higher than that of the 1997 ACR (91 cases; 3.3 per 100,000 [95%CI 2.6 – 4], p=0.015) but similar to 2012 SLICC criteria (114 cases; 4.2 per 100,000 [95%CI, 3.4 – 4.9], p=0.40). (Table 1)

The median time from first disease manifestation to criteria fulfillment was shorter for the EULAR/ACR 2019 criteria (28.47 months) than the 1997 ACR criteria (45.3 months, p< 0.001) and similar to the SLICC 2012 criteria (33.2 months, p=0.89).

The demographic characteristics are detailed in Table 2. Female : male ratio, mean age at classification and the proportion across different races/ethnic groups were similar across the three criteria.

Conclusion: In this population-based study, the incidence of SLE was higher and time to criteria fulfillment sooner by 2019 EULAR/ACR criteria compared to the 1997 ACR but not significantly different than the 2012 SLICC criteria.

Table 1. Age- and sex- adjusted incidence rates by different SLE classification criteria from 2000-2018

Table 2. Demographics of SLE by each criteria


Disclosure: A. Duarte-Garcia, None; M. Hocaoglu, None; S. Osei-Onomah, None; J. Dabit, None; R. Giblon, None; C. Crowson, Myriad Genetics, 1, Pfizer, 1.

To cite this abstract in AMA style:

Duarte-Garcia A, Hocaoglu M, Osei-Onomah S, Dabit J, Giblon R, Crowson C. Incidence and Time to Classification of Systemic Lupus Erythematosus by Three Different Classification Criteria [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/incidence-and-time-to-classification-of-systemic-lupus-erythematosus-by-three-different-classification-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-and-time-to-classification-of-systemic-lupus-erythematosus-by-three-different-classification-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology